Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Rayson

Showing results (21-30 of 86) with videos related to

Pageof 9
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 2015
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?Chris Skedgel, Daniel Rayson, Tallal Younis
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 4, 2009
The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA TrialChris Skedgel, Daniel Rayson, Tallal Younis
Journal of the National Cancer Institute. Monographs|April 14, 2010
The coordination of primary and oncology specialty care at the end of lifePaul K J Han, Daniel Rayson
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 19, 2012
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysisTallal Younis, Daniel Rayson, Kara Thompson
Breast Cancer Research and Treatment|July 20, 2006
The decision-making experience among women diagnosed with stage I and II breast cancerBrenda Sabo, Nathalie St-Jacques, Daniel Rayson
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 6, 2014
Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatmentHazem Assi, Joshua Murray, Laura Boyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Hereditary breast cancer: shared communication and careDaniel Rayson, Patricia Steele, Kelly Collins, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 10, 2011
Compression garments versus compression bandaging in decongestive lymphatic therapy for breast cancer-related lymphedema: a randomized controlled trialMyrna King, Audrey Deveaux, Heather White, et al.
Breast Cancer Research and Treatment|October 5, 2007
Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100Tallal Younis, Daniel Rayson, Marlene Sellon, et al.
Healthcare Policy = Politiques De Sante|August 2, 2012
Quantifying limitations in chemotherapy data in administrative health databases: implications for measuring the quality of colorectal cancer careRobin Urquhart, Daniel Rayson, Geoffrey A Porter, et al.
Pageof 9

Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 2015
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?Chris Skedgel, Daniel Rayson, Tallal Younis
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 4, 2009
The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA TrialChris Skedgel, Daniel Rayson, Tallal Younis
Journal of the National Cancer Institute. Monographs|April 14, 2010
The coordination of primary and oncology specialty care at the end of lifePaul K J Han, Daniel Rayson
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 19, 2012
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysisTallal Younis, Daniel Rayson, Kara Thompson
Breast Cancer Research and Treatment|July 20, 2006
The decision-making experience among women diagnosed with stage I and II breast cancerBrenda Sabo, Nathalie St-Jacques, Daniel Rayson
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 6, 2014
Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatmentHazem Assi, Joshua Murray, Laura Boyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Hereditary breast cancer: shared communication and careDaniel Rayson, Patricia Steele, Kelly Collins, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 10, 2011
Compression garments versus compression bandaging in decongestive lymphatic therapy for breast cancer-related lymphedema: a randomized controlled trialMyrna King, Audrey Deveaux, Heather White, et al.
Breast Cancer Research and Treatment|October 5, 2007
Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100Tallal Younis, Daniel Rayson, Marlene Sellon, et al.
Healthcare Policy = Politiques De Sante|August 2, 2012
Quantifying limitations in chemotherapy data in administrative health databases: implications for measuring the quality of colorectal cancer careRobin Urquhart, Daniel Rayson, Geoffrey A Porter, et al.
Pageof 9